Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Publication | Closed Access

DOI

443

Citations

References

2012

Year

Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale,

The Lancet

Hiv/aids CounsellingMedicineInitial TreatmentAntiviral Drug DevelopmentAntiviral TherapyVirologyCo-formulated ElvitegravirPharmacotherapyHiv-1 InfectionAntiviral DrugHivPharmacologyAntiviral Compound